Blood transfusion for preventing stroke in people with sickle cell disease

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Hirst, Ceri ^a   Wang, Winfred C ^b  

^a ASTRAZENECA   (United Kingdom)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

*Blood transfusion; Anemia, sickle cell *complications ; Child; Humans; Stroke etiology; *prevention control

Indexed keywords

ALLOIMMUNIZATION; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CLINICAL TRIAL; COCHRANE LIBRARY; DOPPLER ECHOGRAPHY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IRON OVERLOAD; PROPHYLAXIS; REVIEW; SICKLE CELL ANEMIA; STROKE;

EID: 77950165211     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003146     Document Type: Review

References (91)

1. STOP 1998 {published data only} Abboud M, Cure J, Gallagher D, Berman B, Hsu L, Wang W, et al. Magnetic resonance angiography (MRA) in children with abnormal transcranial doppler (TCD) velocities in the STOP study [abstract]. Blood 1999;94(10 Suppl 1):645a.
2. Abboud MR, Cure J, Gallagher D, Berman B, Hsu L, Wang W, et al. Magnetic resonance angiography in children with abnormal TCD in the STOP study [abstract]. Proceedings of the 23rd Annual Meeting of the National Sickle Cell Disease Program. 1999:49.
3. Abboud MR, Cure J, Granger S, Gallagher D, Hsu L, Wang W, et al. Magnetic resonance angiography in children with sickle cell disease and abnormal transcranial Doppler ultrasonography findings enrolled in the STOP study.. Blood 2004;103(7):2822-6.
4. Adamkiewicz T, Abboud MR, Barredo JC, Kirby-Allen M, Alvarez OA, Casella JF, et al.Serum ferritin in children with sickle cell disease on chronic transfusion: measure of iron overload or end organ injury? STOP/ STOP II liver iron ancillary study [abstract]. Blood 2006;108(11):Abst 791.
5. Adams RJ. Lessons from the stroke prevention trial in sickle cell anemia (STOP) study. Journal of Child Neurology 2000;15(5):344-9.
6. Adams RJ, Brambilla DJ. Stroke prevention trial in sickle cell anemia: STOP [abstract]. Proceedings of the 21st Annual Meeting of the National Sickle Cell Disease Program. 1996:19.
7. Adams RJ, Brambilla DJ, Granger S, Gallagher D, Vichinsky E, Abboud MR, et al.Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study. Blood 2004;103(10):3689- 94.
8. Adams RJ, Brambilla DJ, McKie V, Files B, Vichinsky E, Abboud M, et al.Risk of stroke in children with sickle cell disease and abnormal transcranial doppler ultrasound (TCD) [abstract]. Blood 1999;94(10 Suppl 1):419a.
9. Adams RJ, Brambilla DJ, McKie V, Files B, Vichinsky E, Abboud M, et al.Stroke prevention in sickle cell disease (STOP): Baseline characteristics of trial patients [abstract]. Proceedings of the 22nd Annual Meeting of the National Sickle Cell Disease Program. 1997:41.
10. Adams RJ, Brambilla DJ, McKie V, Files B, Vichinsky E, Abboud M, et al.Stroke prevention in sickle cell disease (STOP): final results [abstract]. Blood 2000;96(11 Pt 1):10a.
11. Adams RJ, Brambilla DJ, McKie V, Files B, Vichinsky E, Abboud M, et al.Stroke prevention in sickle cell disease (STOP): Final results [abstract]. Proceedings of the 25th Annual Meeting of the National Sickle Cell Disease Program. 2001:Abstract#8.
12. Adams RJ, Brambilla DJ, McKie V, Files B, Vichinsky E, Abboud M, et al.Stroke prevention in sickle cell disease (STOP): follow-up after closure of the trial [abstract]. Blood 1998;92(10 Suppl 1):527a.
13. Adams RJ, Brambilla DJ, McKie VC, Files B, Vichinsky E, Abboud M, et al.Stroke prevention in sickle cell disease (STOP): baseline characteristics of trial patients [abstract]. Blood 1997;90(10 Suppl 1):123a.
14. Adams RJ, Brambilla DJ, Vichinsky E, Abboud M, Pegelow C, Carl EM, et al.Risk of stroke and conversion to abnormal TCD in children screened with transcranial doppler (TCD) during the STOP study [abstract]. Conference Proceedings of the National Sickle Cell Disease Program 30th Annual Meeting; 2002 Sept 17-21. 2002:3.
15. Adams RJ, Brambilla DJ, Vichinsky E, Abboud M, Pegelow C, Carl EM, et al.Stroke prevention trial in sickle cell anemia (STOP study): Risk of stroke in 1933 children screened with transcranial doppler (TCD) [abstract]. Proceedings of the 23rd Annual Meeting of the National Sickle Cell Disease Program. 1999:54.
16. Adams RJ, Carl EM, McKie VC, Odo NA, Kutlar A, Phillips M, et al. A pilot trial of hydroxyurea to prevent strokes in children with sickle cell anemia [abstract]. Proceedings of the 23rd Annual Meeting of the National Sickle Cell Disease Program. 1999:53.
17. Adams RJ, McKie V, Files B, Vichinsky E, Abboud M, Hsu L, et al. Stroke prevention in sickle cell disease (STOP): Results of transcranial doppler ultrasound screening stroke risk [abstract]. Stroke 1998;29(1): 308.
18. Adams RJ, McKie VC, Brambilla DJ, Carl E, Gallagher D, Nichols FT, et al.Stroke prevention trial in sickle cell anemia. Controlled Clinical Trials 1998;19(1):110-29.
19. * Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. New England Journal of Medicine 1998;339(1):5-11.
20. Anonymous. Transfusion to prevent first stroke in children with sickle cell anemia. Journal of the American Ostoepathic Association 1998;98(7):363-4.
21. Bulas DI, Jones A, Seibert JJ, Driscoll C, O'Donnell R, Adams RJ. Transcranial Doppler (TCD) screening for stroke prevention in sickle cell anemia: pitfalls in technique variation. Pediatric Radiology 2000;30(11):733-8.
22. Cohen AR. Sickle cell disease - new treatments, new questions. New England Journal of Medicine 1998;339(1):42-4.
23. Duncan GW. Ischemic stroke in sickle cell disease: a review. Tennessee Medicine 1997;90(12):498-9.
24. Files B, Brambilla D, Kutlar A, Miller S, Pegelow C, Vichinsky E, et al. A randomized trial of chronic transfusion to prevent stroke in sickle cell anemia: changes in ferritin with chronic transfusion [abstract]. Blood 1998;92(10 Suppl 1):528a.
25. Files B, Brambilla D, Kutlar A, Miller S, Vichinsky E, Wang W, et al. Longitudinal changes in ferritin during chronic transfusion: a report from the Stroke Prevention Trial in Sickle Cell Anemia (STOP). Journal of Pediatric Hematology/Oncology 2002;24(4):284-90.
26. Gates A, Rogers MA, Puczynski M. Stroke prevention trial in sickle cell anemia: comments on effects of chronic transfusion on pain [letter]. Journal of Pediatrics 2002;141(5):742-3.
27. Hsu LL, Miller ST, Wright E, Kutlar A, McKie V, Wang W, et al.Alpha thalassemia is associated with decreased risk of abnormal transcranial doppler ultrasonography in children with sickle cell anemia. Journal of Pediatric Hematology/Oncology 2003;25(8):622-8.
28. Kutlar A, Harbin J, Jackson B, Holley L, Gallagher D, Clair B, et al.Laboratory parameters in patients randomized in the STOP study and their modification by transfusion [abstract]. Blood 2000;96(11 Pt 2):18b-9b.
29. Kutlar A, Harbin J, Jackson BB, Holley LGD, Clair B, Brambilla D, et al.Baseline laboratory parameters in patients randomized to the STOP study and their modification by transfusion [abstract]. Proceedings of the 24th Annual Meeting of the National Sickle Cell Disease Program. 2000:82a.
30. Kwiatkowski JL, Brambilla DJ, Granger S, Adams RJ. Elevated blood flow velocity in the anterior cerebral artery and stroke risk in sickle cell disease [abstract]. Blood 2003;102(11):Abst 408.
31. Kwiatkowski JL, Granger S, Brambilla DJ, Brown RC, Miller ST, Adams RJ. Elevated blood flow velocity in the anterior cerebral artery and stroke risk in sickle cell disease: extended analysis from the STOP trial. British Journal of Haematology 2006;134(3):333-9.
32. Kwiatkowski JL, Morales K, Brambilla DJ, Files B, Adamkiewicz T, Adams RJ. Long-term follow-up of transcranial doppler ultrasonography in children with sickle cell disease: Results of the STOP and STOP II patient cohorts [abstract]. Blood 2002;100(11 (Pt 1)):663a.
33. Lee MT, Piomelli S, Granger S, Miller ST, Harkness S, Brambilla DJ, et al.Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. Blood 2006;108(3):847-52.
34. Lee SB, Ramsingh D, Kutlar A, Holley L, McVie VC, Adams RJ. C-reactive protein in children with sickle cell disease at risk for stroke in the STOP study [abstract]. Stroke 2002;33(1):373.
35. Lezcano NE, Odo N, Kutlar A, Brambilla D, Adams RJ. Regular transfusion lowers plasma free hemoglobin in children with sickle-cell disease at risk for stroke. Stroke 2006;37(6):1424-6.
36. Miller ST, Wright E, Abboud M, Berman B, Files B, Scher C, et al.Impact of chronic transfusion on non-neurological events during the Stroke Prevention Trial in sickle cell anemia (STOP) [abstract]. Pediatric Research 2000;47(4 Pt 2):251A.
37. Miller ST, Wright E, Abboud M, Berman B, Files B, Scher C, et al.Impact of chronic transfusion on non-neurological events during the stroke prevention trial in sickle cell anemia (TOP) [abstract]. Proceedings of the 24th Annual Meeting of the National Sickle Cell Disease Program. 2000:61a.
38. Miller ST, Wright E, Abboud M, Berman B, Files B, Scher CD, et al.Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. Journal of Pediatrics 2001;139(6):785-9.
39. Nichols FT, Jones AM, Adams RJ. Stroke prevention in sickle cell disease (STOP) study guidelines for transcranial Doppler testing. Journal of Neuroimaging 2001;11(4):354-62.
40. Olivieri N, Brambilla D, McKie V, Piomelli S, Kutlar A, Files B, et al.Changes in cerebral blood flow velocities during chronic transfusion therapy to prevent stroke in sickle cell disease [abstract]. Blood 2000;96(11 Pt 1):486a.
41. Pegelow CH, Adams R, Hsu L, McKie V, Wang W, Zimmerman R, et al.Children with silent infarct and elevated transcranial doppler ultrasonography velocity are at increased risk of subsequent infarctive events [abstract]. Proceedings of the 23rd Annual Meeting of the National Sickle Cell Disease Program. 1999:137.
42. Pegelow CH, Wang W, Granger S, Hsu LL, Vichinsky E, Moser FG, et al.Silent infarcts in children with sickle cell anemia and abnormal cerebral artery velocity. Archives of Neurology 2001;58(12):2017-21.
43. Styles L, De Jong K, Vichinsky E, Lubin B, Adams R, Kuypers F. Increased RBC phosphatidylserine exposure in sickle cell disease patients at risk for stroke by transcranial Doppler screening [abstract]. Blood 1997;90(10 Suppl 1):604a-5a.
44. Vichinsky E, Luban E, Wright E, Olivieri N, Driscoll C, Pegelow C, et al.Prospective red cell phenotype matching in STOP - a multicentre transfusion trial [abstract]. Proceedings of the 23rd Annual Meeting of the National Sickle Cell Disease Program. 1999:163.
45. Vichinsky E, Luban N, Wright E, Olivieri N, Driscoll C, Pegelow C, et al.Prospective red cell phenotype matching in STOP - a multicenter transfusion trial [abstract]. Blood 1998;92(10 Suppl 1):528a.
46. Vichinsky EP, Luban NL, Wright E, Olivieri N, Driscoll C, Pegelow CH, et al.Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001;41(9):1086-92.
47. Wang W, Morales K, Olivieri N, Styles L, Scher C, Adams R, et al.Effect of chronic transfusion on growth in children with sickle cell anemia: results of the STOP trial [abstract]. National Sickle Cell Disease Program 30th Annual Meeting Conference Proceedings; 2002 Sept 17-21. 2002:100.
48. Wang WC, Morales KH, Scher CD, Styles L, Olivieri N, Adams R, et al.Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial. Journal of Pediatrics 2005;147(2):244-7.
49. STOP 2 2005 {published and unpublished data} Adamkiewicz T, Abboud MR, Barredo JC, Kirby-Allen M, Alvarez OA, Casella JF, et al.Serum ferritin in children with sickle cell disease on chronic transfusion: measure of iron overload or end organ injury? STOP/ STOP II liver iron ancillary study [abstract]. Blood 2006;108(11):Abst 791.
50. Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. New England Journal of Medicine 2005;353(26):2769-78.
51. Adams RJ, Brambilla D, Miller ST. Optimizing primary stroke prevention in children with sickle cell [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9-13; Cincinnati, Ohio. 2005:3.
52. Adams RJ, Brambilla DJ, STOP II investigators. The study design of optimizing primary stroke prevention in children with sickle cell anemia [abstract]. 27th Annual Meeting of the National Sickle Cell Disease Program; 2004 April 18-21; Los Angeles, California. 2004:174.
53. Alvarez O, Miller S, Berman B, Brown C, Casella J, Coates T, et al.Evaluation of chronic transfusion practices in children with sickle cell disease: a survey of STOP II investigators. Blood 2004;104(11): Abstract 3732.
54. ASH News Daily 2004. NHLBI stops the STOP II trial early. www.hematology.org/publications/newsdaily/2004/issue-3/NHLBI.cfm (accessed 22 November 2005).
55. * Brambilla DJ, Adams RJ. Stroke prevention in sickle cell anemia (STOP 2). National Institutes of Health, Clinical Trials Database Started in 06/2000.
56. Brown C, Miller S, Kwiatkowski J, Brambilla D, Adams R. Optimizing primary stroke prevention in sickle cell anemia (STOP 2): an argument for prolonged transfusion?[abstract]. 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 April 8-12; Memphis, USA.. 2006:78.
57. Kwiatkowski JL, Morales K, Brambilla DJ, Files B, Adamkiewicz T, Adams RJ, et al.Long-term follow-up of transcranial doppler ultrasonography in children with sickle cell disease: results of the STOP and STOP II patient cohorts. Blood 2002;100(11 Pt 1):663a.
58. Medical College of Georgia. STOP II Questions and Answers. www.mcg.edu/neurology/Research/sicklecell/STOPIIQandA.htm (accessed 22 November 2005).
59. Medical News Today. NHLBI stops sickle cell anemia transfusion study. www.medicalnewstoday.com/printerfriendlynews.php? newsid=17363 (accessed 22 November 2005).
60. DeBaun 2005 {published data only} DeBaun M. Epidemiology and treatment of silent strokes in sickle cell anemia [abstract]. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9-13; Cincinnati, Ohio. 2005: Plenary.
61. Ware 2006 {published data only} Ware RE, McMurray MA, Schultz WH, Alvarez OA, Aygun B, Cavalier ME, et al.Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke [abstract]. Blood 2006;108(11):Abst 1213.
62. Adams 1992 Adams RJ, Nichols FT, Figueroa R, McKie V, Lott T. Transcranial Doppler correlation with cerebral angiography in sickle cell disease. Stroke 1992;23(8):1073-7.
63. Adams 1996 Adams DM, Schultz WH, Ware RE, Kinney TR. Erythrocytapheresis can reduce iron overload and prevent the need for chelation therapy in chronically transfused pediatric patients. Journal of Pediatric Hematology Oncology 1996;18(1):46-50.
64. Adams 1998a Adams RJ, McKie VC, Brambilla D, Carl E, Gallagher D, Nichols FT, et al.Stroke prevention trial in sickle cell anemia. Controlled Clinical Trials 1998;19(1):110-29.
65. Adams 1998b Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al.Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. New England Journal of Medicine 1998;339(1):5-11.
66. Cohen 1992 Cohen AR, Martin MB, Silber JH, Kim HC, Ohene-Frempong K, Schwarz E. A modified program for prevention of stroke in sickle cell disease. Blood 1992;79(7):1657-61.
67. Cohen 1996 Cohen AR, Norris CF, Smith-Whitley K. Transfusion therapy for sickle cell disease. In: Capon SM, Chambers LA editor(s). New Directions in Pediatric Hematology. Bethesda MD: American Association of Blood Banks, 1996:39-85.
68. Davies 1995 Davies SC, Olatunji PO. Blood transfusion in sickle cell disease. Vox Sanguinis 1995;68(3):145-51.
69. Hickman 1999 Hickman M, Modell B, Greengross P, Chapman C, Layton M, Falconer S, et al.Mapping the prevalence of sickle cell and beta thalassaemia in England: estimating and validating ethnic-specific rates. British Journal of Haematology 1999;104(4):860-7.
70. Jones 2001 Jones AP, Davies SC, Olujohungbe A. Hydroxyurea for sickle cell disease. Cochrane Database of Systematic Reviews 2001, Issue 2. [DOI: 10.1002/14651858]
71. Kinney 1999 Kinney TR, Sleeper LA, Wang WC, Zimmerman RA, Pegelow CH, Ohene-Frempong K, et al.Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. Pediatrics 1999;103(3):640-5.
72. Lee 2006 Lee MT, Piomelli S, Granger S, Miller ST, Harkness S, Brambilla DJ, et al.Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. Blood 2006;108(3):847-52.
73. Miller 2001 Miller ST, Wright E, Abboud M, Berman B, Files B, Scher CD, et al.Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. Journal of Pediatrics 2001;139(6):785-9.
74. Ohene-Frempong 1999 Ohene-Frempong K. Sickle cell disease in the United States of America and Africa. Hematology (American Society of Hematology Education Program). American Society of Hematology, 1999:64-72.
75. Pegelow 1995 Pegelow CH, Adams RJ, McKie V, Abboud M, Berman B, Miller ST, et al.Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. Journal of Pediatrics 1995;126(6):896-9.
76. Pegelow 2001 Pegelow CH, Wang W, Granger S, Hsu LL, Vichinsky E, Moser FG, et al.Silent infarcts in children with sickle cell anemia and abnormal cerebral artery velocity. Archives of Neurology 2001;58(12):2017- 21.
77. Platt 1994 Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al.Mortality in sickle cell disease: life expectancy and risk factors for early death. New England Journal of Medicine 1994;330(23):1639-44.
78. Powars 2000 Powars DR. Management of cerebral vasculopathy in children with sickle cell anaemia. British Journal of Hematology 2000;108(4):666-78.
79. Rana 1997 Rana S, Houston PE, Surana N, Shalaby-Rana EI, Castro OL. Discontinuation of long-term transfusion therapy in patients with sickle cell disease and stroke. Journal of Pediatrics 1997;131(5):757-60.
80. Sarnaik 1979 Sarnaik S, Soorya D, Kim J, Ravindranath Y, Lusher J. Periodic transfusions for sickle cell anemia and CNS infarction. American Journal of Diseases of Children 1979;133(12):1254-7.
81. Sarnaik 1998 Sarnaik SA. Prevention of stroke by transfusions in children with sickle cell anemia. New England Journal of Medicine 1998;339(20):1477-8.
82. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated wtih estimates of treatment effects in controlled trials. JAMA 1995;273(5):408- 12.
83. Serjeant 1992 Serjeant GR. Surgery and anaesthesia. Sickle Cell Disease. 2nd Edition. Oxford: Oxford University Press, 1992:455-8.
84. Steinberg 1999 Steinberg MH. Management of sickle cell disease. New England Journal of Medicine 1999;340(13):1021-30.
85. Styles 1994 Styles LA, Vichinsky E. Effects of a long-term transfusion regimen on sickle cell-related illnesses. Journal of Pediatrics 1994;125(6 Pt 1):909-11.
86. Vichinsky 1990 Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B. Alloimmunization in sickle cell anaemia and transfusion of racially unmatched blood. New England Journal of Medicine 1990;322(23):1617-21.
87. Wang 1991 Wang W, Kovnar EH, Tonkin IL, Mulhern RK, Langston JW, Day S, et al.High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. Journal of Pediatrics 1991;118(3):377-82.
88. Wang 2005 Wang WC, Morales KH, Scher CD, Styles L, Olivieri N, Adams R, et al.Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial. Journal of Pediatrics 2005;147(2):244-7.
89. Ware 1999 Ware RE, Zimmerman SA, Schultz WH. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood 1999;94(9):3022-6.
90. Wayne 2000 Wayne AS, Schoenike SE, Pegelow CH. Financial analysis of chronic transfusion for stroke prevention in sickle cell disease. Blood 2000;96(7):2369-72.
91. Wilimas 1980 Wilimas J, Goff JR, Anderson HR, Langston JW, Thomson E. Efficacy of transfusion therapy for one to two years in patients with sickle cell disease and cerebrovascular accidents. Journal of Pediatrics 1980;96(2):205-8.